title: Personalizing antiplatelet therapy with clopidogrel.
abstract: Dual antiplatelet therapy with aspirin and clopidogrel is the accepted standard for prevention of ischemic complications after percutaneous coronary intervention and has been shown to reduce cardiovascular events in patients with acute coronary syndromes (ACSs). There is substantial interindividual variability in antiplatelet response to clopidogrel. Various clinical studies have demonstrated that patients with high on-clopidogrel platelet reactivity incur an increased risk for ischemic events. In recent years, several clinical and demographic variables as well as multiple genetic factors contributing to the variability in antiplatelet response to clopidogrel have been identified. We discuss strategies based on platelet function testing or genotyping for improvement of antiplatelet effects of clopidogrel and thereby clinical outcome.
authors.affiliation: Universitäts-Herzzentrum Freiburg-Bad Krozingen, Klinik für Kardiologie und Angiologie II, Bad Krozingen, Germany. dietmar.trenk@universitaets-herzzentrum.de
authors.forename: D
authors.initials: D
authors.lastname: Trenk
authors.forename: O
authors.initials: O
authors.lastname: Zolk
authors.forename: M F
authors.initials: MF
authors.lastname: Fromm
authors.forename: F-J
authors.initials: FJ
authors.lastname: Neumann
authors.forename: W
authors.initials: W
authors.lastname: Hochholzer
mesh_terms: D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D000077144:Clopidogrel; D005838:Genotype; D006801:Humans; D010641:Phenotype; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D057285:Precision Medicine / Q000379:methods* / Q000639:trends; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine